John Newman
Stock Analyst at Canaccord Genuity
(2.17)
# 2,921
Out of 5,182 analysts
95
Total ratings
45.24%
Success rate
-6.24%
Average return
Main Sectors:
Stocks Rated by John Newman
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| TYRA Tyra Biosciences | Initiates: Buy | $50 | $35.26 | +41.80% | 1 | Apr 6, 2026 | |
| TNGX Tango Therapeutics | Initiates: Buy | $30 | $19.95 | +50.38% | 1 | Apr 2, 2026 | |
| MCRB Seres Therapeutics | Maintains: Buy | $22 | $8.33 | +164.11% | 11 | Mar 13, 2026 | |
| CADL Candel Therapeutics | Maintains: Buy | $25 | $4.83 | +417.60% | 3 | Mar 13, 2026 | |
| ALLO Allogene Therapeutics | Maintains: Buy | $14 | $2.72 | +414.71% | 4 | Mar 13, 2026 | |
| BNTX BioNTech SE | Maintains: Buy | $171 | $95.50 | +79.06% | 9 | Mar 11, 2026 | |
| ATRA Atara Biotherapeutics | Downgrades: Hold | $25 → $6 | $4.65 | +29.03% | 7 | Jan 13, 2026 | |
| ACET Adicet Bio | Maintains: Buy | $128 → $18 | $6.76 | +166.27% | 7 | Jan 6, 2026 | |
| ACLX Arcellx | Maintains: Buy | $130 | $114.83 | +13.21% | 10 | Dec 8, 2025 | |
| REGN Regeneron Pharmaceuticals | Maintains: Buy | $850 → $1,057 | $748.87 | +41.15% | 20 | Dec 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $10 | $5.17 | +93.42% | 1 | Dec 3, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $126 | $102.74 | +22.64% | 1 | Nov 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $21 | $10.04 | +109.16% | 2 | Oct 21, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $8 | $1.75 | +357.14% | 1 | Mar 5, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $38 → $43 | $5.98 | +619.06% | 1 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $5 | $0.93 | +437.63% | 2 | Jun 23, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $52 → $44 | $32.92 | +33.66% | 9 | Feb 16, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $30 → $38 | $15.24 | +149.34% | 2 | Oct 17, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $12 → $27 | $1.78 | +1,416.85% | 2 | Sep 13, 2017 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Speculative Buy | n/a | $15.76 | - | 1 | Sep 13, 2017 |
Tyra Biosciences
Apr 6, 2026
Initiates: Buy
Price Target: $50
Current: $35.26
Upside: +41.80%
Tango Therapeutics
Apr 2, 2026
Initiates: Buy
Price Target: $30
Current: $19.95
Upside: +50.38%
Seres Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $22
Current: $8.33
Upside: +164.11%
Candel Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $25
Current: $4.83
Upside: +417.60%
Allogene Therapeutics
Mar 13, 2026
Maintains: Buy
Price Target: $14
Current: $2.72
Upside: +414.71%
BioNTech SE
Mar 11, 2026
Maintains: Buy
Price Target: $171
Current: $95.50
Upside: +79.06%
Atara Biotherapeutics
Jan 13, 2026
Downgrades: Hold
Price Target: $25 → $6
Current: $4.65
Upside: +29.03%
Adicet Bio
Jan 6, 2026
Maintains: Buy
Price Target: $128 → $18
Current: $6.76
Upside: +166.27%
Arcellx
Dec 8, 2025
Maintains: Buy
Price Target: $130
Current: $114.83
Upside: +13.21%
Regeneron Pharmaceuticals
Dec 4, 2025
Maintains: Buy
Price Target: $850 → $1,057
Current: $748.87
Upside: +41.15%
Dec 3, 2025
Initiates: Buy
Price Target: $10
Current: $5.17
Upside: +93.42%
Nov 12, 2025
Initiates: Buy
Price Target: $126
Current: $102.74
Upside: +22.64%
Oct 21, 2025
Maintains: Buy
Price Target: $21
Current: $10.04
Upside: +109.16%
Mar 5, 2025
Initiates: Buy
Price Target: $8
Current: $1.75
Upside: +357.14%
Jul 3, 2024
Maintains: Buy
Price Target: $38 → $43
Current: $5.98
Upside: +619.06%
Jun 23, 2023
Reiterates: Buy
Price Target: $5
Current: $0.93
Upside: +437.63%
Feb 16, 2022
Maintains: Buy
Price Target: $52 → $44
Current: $32.92
Upside: +33.66%
Oct 17, 2017
Maintains: Buy
Price Target: $30 → $38
Current: $15.24
Upside: +149.34%
Sep 13, 2017
Maintains: Buy
Price Target: $12 → $27
Current: $1.78
Upside: +1,416.85%
Sep 13, 2017
Downgrades: Speculative Buy
Price Target: n/a
Current: $15.76
Upside: -